Q4 2019 Earnings Estimate for Charles River Laboratories Intl. Inc Issued By KeyCorp (NYSE:CRL)

Charles River Laboratories Intl. Inc (NYSE:CRL) – Investment analysts at KeyCorp lifted their Q4 2019 EPS estimates for Charles River Laboratories Intl. in a research note issued on Wednesday, November 6th. KeyCorp analyst D. Hooker now expects that the medical research company will post earnings of $1.83 per share for the quarter, up from their previous forecast of $1.82.

Charles River Laboratories Intl. (NYSE:CRL) last released its quarterly earnings data on Wednesday, November 6th. The medical research company reported $1.69 earnings per share for the quarter, beating the consensus estimate of $1.64 by $0.05. Charles River Laboratories Intl. had a net margin of 8.94% and a return on equity of 22.01%. The firm had revenue of $668.00 million during the quarter, compared to analysts’ expectations of $674.08 million. During the same period in the previous year, the company earned $1.53 earnings per share. The firm’s quarterly revenue was up 14.1% on a year-over-year basis.

Other research analysts have also recently issued reports about the stock. SunTrust Banks boosted their price objective on shares of Charles River Laboratories Intl. from $156.00 to $162.00 and gave the company a “buy” rating in a report on Monday, September 16th. UBS Group decreased their price objective on shares of Charles River Laboratories Intl. from $147.00 to $145.00 and set a “neutral” rating for the company in a report on Thursday. Credit Suisse Group set a $138.00 price objective on shares of Charles River Laboratories Intl. and gave the company a “hold” rating in a report on Friday, September 13th. Bank of America cut shares of Charles River Laboratories Intl. from a “buy” rating to a “neutral” rating and set a $150.00 price objective for the company. in a report on Friday, October 18th. Finally, ValuEngine cut shares of Charles River Laboratories Intl. from a “buy” rating to a “hold” rating in a report on Thursday, August 1st. Eight investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. Charles River Laboratories Intl. currently has an average rating of “Buy” and an average target price of $150.31.

Shares of CRL traded up $3.14 during mid-day trading on Friday, hitting $130.51. 320,134 shares of the company traded hands, compared to its average volume of 360,739. The company has a debt-to-equity ratio of 1.47, a quick ratio of 1.38 and a current ratio of 1.59. The stock has a 50-day moving average price of $132.31 and a two-hundred day moving average price of $133.44. Charles River Laboratories Intl. has a 1 year low of $103.00 and a 1 year high of $149.07. The stock has a market cap of $6.23 billion, a price-to-earnings ratio of 21.64, a P/E/G ratio of 2.00 and a beta of 1.08.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Squar Milner Financial Services LLC boosted its position in shares of Charles River Laboratories Intl. by 253.2% in the third quarter. Squar Milner Financial Services LLC now owns 219 shares of the medical research company’s stock worth $28,000 after purchasing an additional 157 shares during the period. Hussman Strategic Advisors Inc. bought a new position in shares of Charles River Laboratories Intl. during the third quarter worth $33,000. Flagship Harbor Advisors LLC boosted its position in shares of Charles River Laboratories Intl. by 132.1% during the second quarter. Flagship Harbor Advisors LLC now owns 318 shares of the medical research company’s stock worth $45,000 after acquiring an additional 181 shares during the last quarter. CWM LLC boosted its position in shares of Charles River Laboratories Intl. by 75.9% during the third quarter. CWM LLC now owns 387 shares of the medical research company’s stock worth $51,000 after acquiring an additional 167 shares during the last quarter. Finally, Steward Partners Investment Advisory LLC bought a new position in shares of Charles River Laboratories Intl. during the second quarter worth $69,000. Institutional investors own 94.31% of the company’s stock.

In related news, insider David Ross Smith sold 1,249 shares of the business’s stock in a transaction that occurred on Monday, August 12th. The shares were sold at an average price of $130.36, for a total transaction of $162,819.64. Following the completion of the sale, the insider now directly owns 19,327 shares in the company, valued at $2,519,467.72. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 1.80% of the company’s stock.

Charles River Laboratories Intl. Company Profile

Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates in three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).

Featured Story: Municipal Bonds

Earnings History and Estimates for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply